Chikungunya virus entry is strongly inhibited by phospholipase A2 isolated from the venom of Crotalus durissus terrificus.

Animals Cell Line Chikungunya virus / drug effects Cricetinae Crotalid Venoms / enzymology Crotalus Glycoproteins / metabolism Molecular Docking Simulation Phospholipases A2 / isolation & purification Protein Binding Virus Internalization / drug effects Virus Replication / drug effects

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
22 04 2021
Historique:
received: 22 01 2021
accepted: 06 04 2021
entrez: 23 4 2021
pubmed: 24 4 2021
medline: 16 11 2021
Statut: epublish

Résumé

Chikungunya virus (CHIKV) is the etiologic agent of Chikungunya fever, a globally spreading mosquito-borne disease. There is no approved antiviral or vaccine against CHIKV, highlighting an urgent need for novel therapies. In this context, snake venom proteins have demonstrated antiviral activity against several viruses, including arboviruses which are relevant to public health. In particular, the phospholipase A2

Identifiants

DOI: 10.1038/s41598-021-88039-4 PMID: 33888774 PMC: PMC8062466
pubmed: 33888774
doi: 10.1038/s41598-021-88039-4
pii: 10.1038/s41598-021-88039-4
pmc: PMC8062466
doi:

Substances chimiques

Crotalid Venoms 0
Glycoproteins 0
Phospholipases A2 EC 3.1.1.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8717

Subventions

Organisme : Wellcome Trust
ID : 096670
Pays : United Kingdom

Références

Chen, R. et al. ICTV virus taxonomy profile: Togaviridae. J. Gen. Virol. 99, 761–762 (2018).
pubmed: 29745869 doi: 10.1099/jgv.0.001072
Mayer, S. V., Tesh, R. B. & Vasilakis, N. The emergence of arthropod-borne viral diseases: A global prospective on dengue, chikungunya and zika fevers. Acta Trop. 166, 155–163 (2017).
pubmed: 27876643 doi: 10.1016/j.actatropica.2016.11.020
Burt, F. J. et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect. Dis. 17, e107–e117 (2017).
pubmed: 28159534 doi: 10.1016/S1473-3099(16)30385-1
Strauss, J. H. & Strauss, E. G. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58, 491–562 (1994).
pubmed: 7968923 pmcid: 372977 doi: 10.1128/mr.58.3.491-562.1994
Yap, M. L. et al. Structural studies of Chikungunya virus maturation. Proc. Natl. Acad. Sci. U. S. A. 114, 13703–13707 (2017).
pubmed: 29203665 pmcid: 5748190 doi: 10.1073/pnas.1713166114
Weaver, S. C. & Forrester, N. L. Chikungunya: Evolutionary history and recent epidemic spread. Antiviral Res. 120, 32–39 (2015).
pubmed: 25979669 doi: 10.1016/j.antiviral.2015.04.016
Mason, P. J. & Haddow, A. J. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–1953. Trans. R. Soc. Trop. Med. Hyg. 51, 238–240 (1957).
pubmed: 13443013 doi: 10.1016/0035-9203(57)90022-6
Mavale, M. et al. Venereal transmission of chikungunya virus by Aedes aegypti mosquitoes (Diptera: Culicidae). Am. J. Trop. Med. Hyg. 83, 1242–1244 (2010).
pubmed: 21118928 pmcid: 2990038 doi: 10.4269/ajtmh.2010.09-0577
Ngoagouni, C., Kamgang, B., Kazanji, M., Paupy, C. & Nakouné, E. Potential of Aedes aegypti and Aedes albopictus populations in the Central African Republic to transmit enzootic chikungunya virus strains. Parasit. Vectors 10, 164 (2017).
pubmed: 28347325 pmcid: 5368999 doi: 10.1186/s13071-017-2101-0
Kraemer, M. U. G. et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. Albopictus. Elife 4, (2015).
Silva, L. A., Dermody, T. S., Silva, L. A. & Dermody, T. S. Chikungunya virus : epidemiology, replication, disease mechanisms, and prospective intervention strategies Find the latest version : Chikungunya virus : epidemiology , replication , disease mechanisms , and prospective intervention strategies. 127, 737–749 (2017).
Nunes, M. R. T. et al. Emergence and potential for spread of Chikungunya virus in Brazil. BMC Med. 13, 102 (2015).
pubmed: 25976325 pmcid: 4433093 doi: 10.1186/s12916-015-0348-x
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Situação epidemiológica da síndrome congênita associada à infecção pelo vírus Zika em 2020: até a SE 26. Bol. Epidemiológico 51, 23–28 (2020).
Das, T. et al. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog. Neurobiol. 91, 121–129 (2010).
pubmed: 20026374 doi: 10.1016/j.pneurobio.2009.12.006
Powers, A. M., Brault, A. C., Tesh, R. B. & Weaver, S. C. Re-emergence of chikungunya and o’nyong-nyong viruses: Evidence for distinct geographical lineages and distant evolutionary relationships. J. Gen. Virol. 81, 471–479 (2000).
pubmed: 10644846
Dupuis-Maguiraga, L. et al. Chikungunya disease: Infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia. PLoS Negl. Trop. Dis. 6, e1446 (2012).
pubmed: 22479654 pmcid: 3313943 doi: 10.1371/journal.pntd.0001446
Gardner, J. et al. Chikungunya virus arthritis in adult wild-type mice. J. Virol. 84, 8021–8032 (2010).
pubmed: 20519386 pmcid: 2916516 doi: 10.1128/JVI.02603-09
Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), D. of V.-B. D. (DVBD) et al. Symptoms, Diagnosis, & Treatment | Chikungunya virus | CDC. https://www.cdc.gov/chikungunya/symptoms/index.html (2018).
Dias, D. A., Urban, S. & Roessner, U. A historical overview of natural products in drug discovery. Metabolites 2, 303–336 (2012).
pubmed: 24957513 pmcid: 3901206 doi: 10.3390/metabo2020303
Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 83, 770–803 (2020).
pubmed: 32162523 doi: 10.1021/acs.jnatprod.9b01285
Bailey, P. & Wilce, J. Venom as a source of useful biologically active molecules. Emerg. Med. Australas. 13, 28–36 (2001).
Villalta-Romero, F. Discovery of small molecule inhibitors for the snake venom metalloprotease BaP1 using in silico and in vitro tests. Bioorg. Med. Chem. Lett. 27, 2018–2022 (2017).
pubmed: 28347665 doi: 10.1016/j.bmcl.2017.03.007
Burke, J. E. & Dennis, E. A. Phospholipase A2 Biochemistry. Cardiovasc. Drugs Ther. 23, 49–59 (2009).
pubmed: 18931897 doi: 10.1007/s10557-008-6132-9
Calderon, L. A. et al. Antitumoral activity of snake venom proteins: New trends in cancer therapy. Biomed Res. Int. 2014, 1–19 (2014).
doi: 10.1155/2014/203639
Filkin, S. Y., Lipkin, A. V. & Fedorov, A. N. Phospholipase superfamily: Structure, functions, and biotechnological applications. Biochem. 85, 177–195 (2020).
Schaloske, R. H. & Dennis, E. A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1761, 1246–1259 (2006).
Six, D. A. & Dennis, E. A. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1488, 1–19 (2000).
Hendon, R. A. & Fraenkel-Conrat, H. Biological roles of the two components of crotoxin. Proc. Natl. Acad. Sci. 68, 1560–1563 (1971).
pubmed: 5283946 doi: 10.1073/pnas.68.7.1560 pmcid: 389240
FAURE, G. et al. The origin of the diversity of crotoxin isoforms in the venom of Crotalus durissus terrificus. Eur. J. Biochem. 223, 161–164 (1994).
Almeida, J. R. et al. CoaTx-II, a new dimeric Lys49 phospholipase A2 from Crotalus oreganus abyssus snake venom with bactericidal potential: Insights into its structure and biological roles. Toxicon 120, 147–158 (2016).
pubmed: 27530662 doi: 10.1016/j.toxicon.2016.08.007
de Carvalho, A. E. Z. et al. Crotalus durissus ruruima Snake Venom and a Phospholipase A 2 Isolated from This Venom Elicit Macrophages to Form Lipid Droplets and Synthesize Inflammatory Lipid Mediators. J. Immunol. Res. 2019, 1–12 (2019).
Shimizu, J. F. et al. Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle. PLoS ONE 12, e0187857 (2017).
pubmed: 29141010 pmcid: 5687739 doi: 10.1371/journal.pone.0187857
Muller, V. D. et al. Phospholipase A2 isolated from the venom of Crotalus durissus terrificus inactivates dengue virus and other enveloped viruses by disrupting the viral envelope. PLoS ONE 9, 1–10 (2014).
doi: 10.1371/journal.pone.0112351
Muller, V. D. M. et al. Crotoxin and phospholipases A2 from Crotalus durissus terrificus showed antiviral activity against dengue and yellow fever viruses. Toxicon 59, 507–515 (2012).
pubmed: 21723310 doi: 10.1016/j.toxicon.2011.05.021
Russo, R. R. et al. Expression, purification and virucidal activity of two recombinant isoforms of phospholipase A2 from Crotalus durissus terrificus venom. Arch. Virol. 164, 1159–1171 (2019).
pubmed: 30809709 doi: 10.1007/s00705-019-04172-6
Matkovic, R. et al. The host DHX9 DExH-Box helicase is recruited to chikungunya virus replication complexes for optimal genomic RNA translation. J. Virol. 93, 1–17 (2018).
Pohjala, L. et al. Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. PLoS ONE 6, e28923 (2011).
pubmed: 22205980 pmcid: 3242765 doi: 10.1371/journal.pone.0028923
Derenne, A., Derfoufi, K.-M., Cowper, B., Delporte, C. & Goormaghtigh, E. FTIR spectroscopy as an analytical tool to compare glycosylation in therapeutic monoclonal antibodies. Anal. Chim. Acta 1112, 62–71 (2020).
pubmed: 32334683 doi: 10.1016/j.aca.2020.03.038
Khajehpour, M., Dashnau, J. L. & Vanderkooi, J. M. Infrared spectroscopy used to evaluate glycosylation of proteins. Anal. Biochem. 348, 40–48 (2006).
pubmed: 16298329 doi: 10.1016/j.ab.2005.10.009
Movasaghi, Z., Rehman, S. & ur Rehman, D. I. Fourier Transform Infrared (FTIR) Spectroscopy of Biological Tissues. Appl. Spectrosc. Rev. 43, 134–179 (2008).
Chen, M. et al. Broad-spectrum antiviral agents: secreted phospholipase A2 targets viral envelope lipid bilayers derived from the endoplasmic reticulum membrane. Sci. Rep. 7, 15931 (2017).
pubmed: 29162867 pmcid: 5698466 doi: 10.1038/s41598-017-16130-w
Fenard, D. et al. Secreted phospholipases A2, a new class of HIV inhibitors that block virus entry into host cells. J. Clin. Invest. 104, 611–618 (1999).
pubmed: 10487775 pmcid: 408539 doi: 10.1172/JCI6915
Gutiérrez, J. M. & Lomonte, B. Phospholipases A2: Unveiling the secrets of a functionally versatile group of snake venom toxins. Toxicon 62, 27–39 (2013).
pubmed: 23025922 doi: 10.1016/j.toxicon.2012.09.006
Murakami, M. et al. The roles of the secreted phospholipase A2 gene family in immunology. in 91–134 (2016). https://doi.org/10.1016/bs.ai.2016.05.001 .
Palm, N. W. et al. Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity. Immunity 39, 976–985 (2013).
pubmed: 24210353 doi: 10.1016/j.immuni.2013.10.006
Sadekuzzaman, M., Stanley, D. & Kim, Y. Nitric oxide mediates insect cellular immunity via phospholipase A2 activation. J. Innate Immun. 10, 70–81 (2018).
pubmed: 29035888 doi: 10.1159/000481524
Brenes, H., Loría, G. D. & Lomonte, B. Potent virucidal activity against Flaviviridae of a group IIA phospholipase A2 isolated from the venom of Bothrops asper. Biologicals 63, 48–52 (2020).
pubmed: 31839332 doi: 10.1016/j.biologicals.2019.12.002
Song, H. et al. Molecular basis of arthritogenic alphavirus receptor MXRA8 binding to chikungunya virus envelope protein. Cell 177, 1714-1724.e12 (2019).
pubmed: 31080063 doi: 10.1016/j.cell.2019.04.008
Salvador, B., Zhou, Y., Michault, A., Muench, M. O. & Simmons, G. Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology 393, 33–41 (2009).
pubmed: 19692105 doi: 10.1016/j.virol.2009.07.013
Wengler, G., Koschinski, A., Wengler, G. & Dreyer, F. Entry of alphaviruses at the plasma membrane converts the viral surface proteins into an ion-permeable pore that can be detected by electrophysiological analyses of whole-cell membrane currents. J. Gen. Virol. 84, 173–181 (2003).
pubmed: 12533714 doi: 10.1099/vir.0.18696-0
Rashad, A. A. & Keller, P. A. Structure based design towards the identification of novel binding sites and inhibitors for the chikungunya virus envelope proteins. J. Mol. Graph. Model. 44, 241–252 (2013).
pubmed: 23911992 doi: 10.1016/j.jmgm.2013.07.001
Jose, J., Snyder, J. E. & Kuhn, R. J. A structural and functional perspective of alphavirus replication and assembly NIH Public Access. Futur. Microbiol 4, 837–856 (2009).
doi: 10.2217/fmb.09.59
Kielian, M., Chanel-Vos, C. & Liao, M. Alphavirus entry and membrane fusion. Viruses 2, 796–825 (2010).
pubmed: 21546978 pmcid: 3086016 doi: 10.3390/v2040796
Sánchez-San Martín, C., Sosa, H. & Kielian, M. A Stable prefusion intermediate of the alphavirus fusion protein reveals critical features of class II membrane fusion. Cell Host Microbe 4, 600–608 (2008).
Oliveira, D. M. de et al. Organometallic complex strongly impairs chikungunya virus entry to the host cells. Front. Microbiol. 11, (2020).
Schneidman-Duhovny, D., Inbar, Y., Nussinov, R. & Wolfson, H. J. PatchDock and SymmDock: Servers for rigid and symmetric docking. Nucleic Acids Res. 33, W363–W367 (2005).
pubmed: 15980490 pmcid: 1160241 doi: 10.1093/nar/gki481
Andrusier, N., Nussinov, R. & Wolfson, H. J. FireDock: Fast interaction refinement in molecular docking. Proteins Struct. Funct. Bioinforma. 69, 139–159 (2007).
doi: 10.1002/prot.21495
Laskowski, R. A. & Swindells, M. B. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778–2786 (2011).
pubmed: 21919503 doi: 10.1021/ci200227u

Auteurs

Igor Andrade Santos (IA)

Institute of Biomedical Science (ICBIM), Federal University of Uberlândia (UFU), Avenida Amazonas, 4C- Room 216, Umuarama, Uberlândia, Minas Gerais, CEP: 38405-302, Brazil.

Jacqueline Farinha Shimizu (JF)

Institute of Biomedical Science (ICBIM), Federal University of Uberlândia (UFU), Avenida Amazonas, 4C- Room 216, Umuarama, Uberlândia, Minas Gerais, CEP: 38405-302, Brazil.
Institute of Biosciences, Humanities and Exact Sciences (Ibilce), São Paulo State University (Unesp), Campus São José do Rio Preto, São José do Rio Preto, SP, Brazil.

Débora Moraes de Oliveira (DM)

Institute of Biomedical Science (ICBIM), Federal University of Uberlândia (UFU), Avenida Amazonas, 4C- Room 216, Umuarama, Uberlândia, Minas Gerais, CEP: 38405-302, Brazil.

Daniel Oliveira Silva Martins (DOS)

Institute of Biomedical Science (ICBIM), Federal University of Uberlândia (UFU), Avenida Amazonas, 4C- Room 216, Umuarama, Uberlândia, Minas Gerais, CEP: 38405-302, Brazil.
Institute of Biosciences, Humanities and Exact Sciences (Ibilce), São Paulo State University (Unesp), Campus São José do Rio Preto, São José do Rio Preto, SP, Brazil.

Léia Cardoso-Sousa (L)

Institute of Biomedical Science (ICBIM), Federal University of Uberlândia (UFU), Avenida Amazonas, 4C- Room 216, Umuarama, Uberlândia, Minas Gerais, CEP: 38405-302, Brazil.

Adélia Cristina Oliveira Cintra (ACO)

Department of Clinical, Toxicological and Bromatological Analyses, School of Pharmaceutical Sciences of Ribeirao Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

Victor Hugo Aquino (VH)

Department of Clinical, Toxicological and Bromatological Analyses, School of Pharmaceutical Sciences of Ribeirao Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

Suely Vilela Sampaio (SV)

Department of Clinical, Toxicological and Bromatological Analyses, School of Pharmaceutical Sciences of Ribeirao Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

Nilson Nicolau-Junior (N)

Institute of Biotechnology, Federal University of Uberlândia (UFU), Uberlândia, MG, Brazil.

Robinson Sabino-Silva (R)

Institute of Biomedical Science (ICBIM), Federal University of Uberlândia (UFU), Avenida Amazonas, 4C- Room 216, Umuarama, Uberlândia, Minas Gerais, CEP: 38405-302, Brazil.

Andres Merits (A)

Institute of Technology, University of Tartu, Tartu, Estonia. andres.merits@ut.ee.

Mark Harris (M)

Faculty of Biological Sciences and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK. m.harris@leeds.ac.uk.

Ana Carolina Gomes Jardim (ACG)

Institute of Biomedical Science (ICBIM), Federal University of Uberlândia (UFU), Avenida Amazonas, 4C- Room 216, Umuarama, Uberlândia, Minas Gerais, CEP: 38405-302, Brazil. jardim@ufu.br.
Institute of Biosciences, Humanities and Exact Sciences (Ibilce), São Paulo State University (Unesp), Campus São José do Rio Preto, São José do Rio Preto, SP, Brazil. jardim@ufu.br.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chikungunya virus entry is strongly inhibited...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Chikungunya virus entry is strongly inhibited...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Togaviridae › Alphavirus › Virus du chikungunya › Chikungunya virus entry is strongly inhibited...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Arvicolinae › Cricetinae › Chikungunya virus entry is strongly inhibited...
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Venins › Venins de serpent › Venins de vipère › Venins de crotalidé › Chikungunya virus entry is strongly inhibited...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Reptiles › Serpents › Alethinophidia › Viperidae › Crotalinae › Crotalus › Chikungunya virus entry is strongly inhibited...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Glycoprotéines › Chikungunya virus entry is strongly inhibited...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Simulation numérique › Simulation de docking moléculaire › Chikungunya virus entry is strongly inhibited...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Esterases › Carboxylic ester hydrolases › Phospholipases A › Phospholipases A2 › Chikungunya virus entry is strongly inhibited...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Chikungunya virus entry is strongly inhibited...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Pénétration virale › Chikungunya virus entry is strongly inhibited...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › Chikungunya virus entry is strongly inhibited...